Antithrombotic Therapy Use at Discharge and 1 Year in Patients With Atrial Fibrillation and Acute Stroke | Zendy

Renato D. Lópes | Zendy; Bimal R. Shah | Zendy; DaiWai M. Olson | Zendy; Xin Zhao | Zendy; Wenqin Pan | Zendy; Cheryl Bushnell | Zendy; Eric D. Peterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antithrombotic Therapy Use at Discharge and 1 Year in Patients With Atrial Fibrillation and Acute Stroke

Author(s) -

Renato D. Lópes,

Bimal R. Shah,

DaiWai M. Olson,

Xin Zhao,

Wenqin Pan,

Cheryl Bushnell,

Eric D. Peterson

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.625392

Subject(s) - medicine , warfarin , atrial fibrillation , clopidogrel , aspirin , antithrombotic , stroke (engine) , odds ratio , cardiology , population , acute coronary syndrome , confidence interval , myocardial infarction , mechanical engineering , environmental health , engineering

Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA). However, few studies have examined factors associated with long-term antithrombotic therapy use in IS/TIA patients with AF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research